Dr. Joshua J. McFarlane, MD

Dr. McFarlane practices at Virginia Cancer Institute Incorporated in Richmond, Virginia.

Dr. McFarlane's NPI, 1184847055, was assigned on April 10, 2007. Dr. McFarlane graduated from University of Texas Southwestern Medical School at Dallas in 2003. Dr. McFarlane holds Virginia license 0101245050.

Dr. McFarlane's primary practice is Virginia Cancer Institute Incorporated, at 7202 Glen Forest Dr, Richmond, VA 23226 in Henrico County. The practice phone is (804) 287-3000.

Dr. McFarlane's primary practice is Virginia Cancer Institute Incorporated in Richmond, Virginia. Dr. McFarlane is also affiliated with Bon Secours St. Mary's Hospital. The medical group on file is Virginia Cancer Institute. Dmand AI also links Dr. McFarlane to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McFarlane practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. McFarlane's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. McFarlane's licenses on file in 2 states: Virginia and Tennessee.

CMS data shows 56,176 Medicare services from Dr. McFarlane across 58 procedure codes in 2024, for 947 Medicare patients. Medicare paid $1,669,703 for them.

CMS counts 947 Medicare patients who saw Dr. McFarlane in 2024. The largest group is 65 to 74, with 398 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McFarlane's median patient age at 68, with 56% women.

In 2024, Dr. McFarlane wrote 1,904 Medicare Part D claims for 256 patients. 73% of them were for generic drugs. CMS names the drug for 1,608 of them, across 42 drugs with 11 or more claims each, at $3,710,293 in total drug cost. In 2023, CMS named 1,434 claims across 46 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. McFarlane for performance year 2024, reported individually. Dr. McFarlane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McFarlane as offering telehealth.

CMS Open Payments shows 364 general payments to Dr. McFarlane from 62 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Genentech, Inc. paid the most, $2,482. It also lists 2 research payments totaling $951 in 2021.

Dr. McFarlane graduated from University of Texas Southwestern Medical School at Dallas in 2003.